Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29668300 | 1.00 | BCHE (0.45) | BCHETRPC3TP53MAPTLMNA | |
| SCHEMBL22481486 | 0.88 | NPY5R (0.42) | LMNANAMPTNPY5R | |
| SCHEMBL29668248 | 0.88 | NPY5R (0.42) | LMNANAMPTNPY5R | |
| SCHEMBL22481538 | 0.87 | TRPC3 (0.45) | TRPC3TP53MAPTNAMPTNPY5R | |
| SCHEMBL22481533 | 0.86 | NPY5R (0.40) | LMNANAMPTNPY5R | |
| SCHEMBL29668224 | 0.86 | NPY5R (0.40) | LMNANAMPTNPY5R | |
| SCHEMBL22550840 | 0.85 | NPY5R (0.44) | LMNANAMPTNPY5R | |
| SCHEMBL22464929 | 0.85 | TP53 (0.45) | BCHETRPC3TP53MAPTLMNA | |
| SCHEMBL22481577 | 0.81 | TRPC3 (0.48) | BCHETRPC3TP53MAPTLMNA | |
| SCHEMBL22481378 | 0.81 | TRPC3 (0.48) | BCHETRPC3TP53MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | BCHE 3039/4885TRPC3 9/4885TP53 4010/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | BCHE 3039/4885TRPC3 9/4885TP53 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.